International Clinical Trial: A Single-arm, Single-center, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined with Anlotinib in the Treatment of Second-line and Above Recurrent or Metastatic SMARCA4-deficient Non-small Cell Lung Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131693) titled 'A Single-arm, Single-center, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined with Anlotinib in the Treatment of Second-line and Above Recurrent or Metastatic SMARCA4-deficient Non-small Cell Lung Cancer' on Sept. 5.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

Condition: SMARCA4-deficient non-small cell lung cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-15

Target Sample Size: Trial group:23;

Countr...